About Eton Pharmaceuticals, Inc. 
Eton Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
Company Coordinates 
Company Details
21925 W Field Pkwy Ste 235 , DEER PARK IL : 60010-7208
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 11 Schemes (7.27%)
Foreign Institutions
Held by 23 Foreign Institutions (2.6%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Dr. Norbert Riedel
Independent Chairman of the Board
Mr. Sean Brynjelsen
President, Chief Executive Officer, Director
Mr. Mark Baum
Director
Mr. Charles Casamento
Independent Director
Mr. Paul Maier
Independent Director
Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
Pharmaceuticals & Biotechnology
USD 477 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.20
-14.23%
19.90






